BenQ BM Holding Cayman Corp.
明基醫院集團股份有限公司
(A company incorporated in the Cayman Islands with limited liability)
(Stock Code: 2581)

(1) INSIDE INFORMATION UNAUDITED QUARTERLY CONSOLIDATED FINANCIAL STATEMENTS OF THE CONTROLLING SHAREHOLDER, QISDA CORPORATION, FOR THE THREE MONTHS ENDED MARCH 31, 2026; AND (2) CLARIFICATION IN RELATION TO THE CIRCULAR

UNAUDITED QUARTERLY CONSOLIDATED FINANCIAL STATEMENTS OF QISDA CORPORATION

This announcement is made by BenQ BM Holding Cayman Corp. (明基醫院集團股份有限公司) (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The Company's controlling shareholder, Qisda Corporation (佳世達科技股份有限公司)("**Qisda Corporation**"), is listed on the Taiwan Stock Exchange in Taiwan (stock code: 2352). As at the date of this announcement, Qisda Corporation is deemed to be interested in approximately 74.61% of the total issued share capital of the Company by virtue of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

On May 7, 2026, Qisda Corporation publishes its unaudited quarterly consolidated financial statements (the "**Qisda First Quarterly Results**") for the three months ended March 31, 2026. The Qisda First Quarterly Results are available on the websites of the Taiwan Stock Exchange (https://www.twse.com.tw/en/) and Qisda Corporation (https://www.qisda.com/en). Unless otherwise provided therein, all dollar amounts in the Qisda First Quarterly Results are denominated in Taiwanese dollars.

The unaudited consolidated financial statements of Qisda Corporation contained in the Qisda First Quarterly Results, which include certain financial and operational information which covers the Group, have been prepared in accordance with the applicable accounting principles and practices generally accepted in the Republic of China, which are different from the International Financial Reporting Standards (the "**IFRS**"). Since the Group's financial information is to be prepared in accordance with the applicable IFRS, the financial information contained in the Qisda First Quarterly Results, which covers also the performance of the Group as a subsidiary of Qisda Corporation, may not be directly comparable with the financial results of the Group.

Extract of the Qisda First Quarterly Results

The following is an extract of the selected financial information relating to the Group's performance, extracted from the Qisda First Quarterly Results:

Segment information

	For the three months ended March 31, 2026 Medical *(NTD'000)*	**For the three months ended March 31, 2025 Medical** *(NTD'000)*
External revenue	2,884,138	2,811,761
Intra-group revenue from Qisda Group(Note)	638	796
Total segment revenue	**2,884,776**	**2,812,557**
Segment profit from operations	**34,266**	**101,222**

Note:

This refers to the intra-group revenue from Qisda Corporation and its subsidiaries (other than the Company).

Information of Investees (excluding information on investments in Mainland China)

Investor	Investee	Location	Main Businesses and Products	Original investment Amount March 31, 2026 *(NTD'000)*	Original investment Amount December 31, 2025 *(NTD'000)*	Balances as of March 31, 2026 Shares *('000)*	Balances as of March 31, 2026 Percentage of Ownership	Balances as of March 31, 2026 Carrying Value *(NTD'000)*	Net Income of the Investee *(NTD'000)*	Investment Income *(NTD'000)*	Note
Qisda Corporation	The Company	Cayman Islands	Investment and holding activity	7,789,187	7,789,187	108,555	34.80%	3,572,290	31,561	10,984	Parent/ Subsidiary

Shareholders of the Company and potential investors are advised not to place undue reliance on the Qisda First Quarterly Results and are reminded that the financial information presented therein has not been audited or reviewed by the Company's auditors. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

CLARIFICATION IN RELATION TO THE CIRCULAR

Reference is made to the circular (the "**Circular**") published on April 27, 2026 of the Company for the annual general meeting to be held on June 5, 2026.

The Company would like to clarify inadvertent clerical errors contained on page 7 of the Circular as follows (with the change underlined for easy reference):

"It is currently estimated that the remuneration for the auditor's audit services for 2026 will range from RMB**<u>2.6</u>** million to RMB**<u>3.0</u>** million, the estimate has taken into account, amongst others, the historic fees of the auditor, the expected audit scope and resources required to be committed by the auditor given the Company's business···"

Except as disclosed above, all other information contained in the Circular remains unchanged. This announcement is supplemental to and should be read in conjunction with the Circular.

By order of the Board
BenQ BM Holding Cayman Corp.
Mr. HSIAO Tze-Jung
Executive Director

Hong Kong, May 7, 2026

*As of the date of this announcement, the board (the "**Board**") of directors of the Company (the "**Directors**" and each a "**Director**") comprise: (i) Mr. HSIAO Tze-Jung as an executive Director; (ii) Mr. CHEN Chi-Hong, Ms. HUNG Chiu-Chin and Dr. WANG Liming as non-executive Directors; and (iii) Dr. CHOW Hsing-Yi, Mr. WANG Wen-Tsung and Mr. CHEN Ray-Jade as independent non-executive Directors.*